TTM Technologies, Inc. To Conduct First Quarter FY 2021 Conference Call April 28th, 2021

SANTA ANA, Calif., April 07, 2021 (GLOBE NEWSWIRE) — TTM Technologies, Inc. (NASDAQ:TTMI) will host a conference call on Wednesday, April 28th, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter fiscal year 2021 performance.

Telephone access is available by dialing 800-367-2403 or international 334-777-6978 (ID 7087128). The conference call will also be simulcast on the company’s website, www.ttm.com, and will remain accessible for one week following the live event.

TTM Technologies will release its first quarter fiscal year 2021 financial results after the market closes on Wednesday, April 28, 2021.

About TTM

TTM Technologies, Inc. is a leading global printed circuit board manufacturer, focusing on quick-turn and volume production of technologically advanced PCBs and backplane assemblies as well as a global designer and manufacturer of high-frequency radio frequency (RF) and microwave components and assemblies. TTM stands for time-to-market, representing how TTM’s time-critical, one-stop manufacturing services enable customers to shorten the time required to develop new products and bring them to market. Additional information can be found at www.ttm.com.

Contact:
Sameer Desai,
Senior Director, Corporate
Development & Investor Relations
[email protected] 
714-327-3050



Catalyst Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 07, 2021 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference at 3:00 pm ET on Thursday, April 15, 2021.

To access a live webcast of the presentation, please click here. An archived webcast of the presentation will be available for 90 days on the Events and Presentations section of the Company’s website.

About Catalyst Biosciences, the Protease Medicines company

Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protease engineering platform has generated two late-stage clinical programs, including MarzAA, a subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. Our complement pipeline includes a pre-clinical C3-degrader program partnered with Biogen for dry age-related macular degeneration, an improved complement factor I protease for SQ replacement therapy in patients with CFI deficiency and C4b-degraders designed to target disorders of the classical complement pathway as well as other complement programs in development.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about, the potential benefits of products based on Catalyst’s engineered protease platform, and the Company’s collaboration with Biogen for the development and commercialization of a pre-clinical C3-degrader program dry age-related macular degeneration. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that trials and studies may be delayed as a result of COVID-19, competitive products and other factors, that trials may not have satisfactory outcomes, that additional human trials will not replicate the results from earlier trials, that potential adverse effects may arise from the testing or use of MarzAA, including the generation of neutralizing antibodies, the risk that costs required to develop or manufacture the Company’s products will be higher than anticipated, including as a result of delays in trial enrollment, development and manufacturing resulting from COVID-19 and other factors, the risk that Biogen will terminate Catalyst’s agreement, competition and other risks described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 4, 2021, and in other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.

Contact:

Ana Kapor
Catalyst Biosciences, Inc.
[email protected]



Amdocs Delivers Service and Network Automation Solution to Support Globe Telecom’s Launch of its Network Virtualization Platform

NFV and cloud orchestration capabilities enable Globe to provide on-demand cloud-based network services to enterprises

MANILLA, Philippines and ST. LOUIS, April 07, 2021 (GLOBE NEWSWIRE) — Amdocs (NASDAQ: DOX), a leading provider of software and services to communications and media companies, today announced that Globe Telecom, one of the Philippines’ largest telecommunications providers, has gone live with Amdocs’ service and network automation platform for network functions virtualization (NFV) and cloud orchestration, becoming one of the first telco brands to launch network virtualization and offer virtual network services in the country.

Commenting on the launch, Peter Maquera, SVP and Head of Enterprise Group at Globe Telecom said, “With the help of Amdocs’ service and network automation system, we are offering our enterprise clients multiple virtualized network services and features and providing high security, real-time network visibility and control. Furthermore, we are providing the speed and agility critical to businesses for utilizing new network and cloud services offerings and experiences at a rapid pace, delivering compelling digital experience to their customers.”

With Amdocs’ NFV and cloud orchestration solution, Globe has transformed its network to automate and simplify operations and management of their Network-as-a-Service (NaaS) offering for a wide range of value-added services. This includes Software-Defined Wide Area Network (SD-WAN), security services, bandwidth on-demand, mobile core network related services (vEPC and vIMS), and other value-added applications. It will further empower businesses to connect to cloud resources, enhance and automate branch connectivity, manage and control incoming and outgoing network traffic and enable routing, firewall security, and virtual private network connectivity.

“Globe Telecom is continuously working to meet the evolving needs of digital enterprises and provide them with innovative services at faster speeds. Amdocs’ flexible and intelligent automation solution will enable Globe to provide its enterprise clients with highly-flexible and scalable cloud-based network services that they can easily configure, customize and monitor ensuring an enhanced and seamless digital experience to their end-customers,” said Anthony Goonetilleke, Group President, Media, Network and Technology, Amdocs.

Supporting Resources

About Globe Telecom 
Globe Telecom, Inc. is a leading full-service telecommunications company in the Philippines and publicly listed in the Philippine Stock Exchange with the stock symbol GLO. The company serves the telecommunications and technology needs of consumers and businesses across an entire suite of products and services including mobile, fixed, broadband, data connectivity, internet and managed services. It has major interests in financial technology, digital marketing solutions, venture capital funding for startups, and virtual healthcare. In 2019, Globe became a signatory to the United Nations Global Compact, committing to implement universal sustainability principles. Its principals are Ayala Corporation and Singtel, acknowledged industry leaders in the country and in the region. For more information, visit www.globe.com.ph. Follow @enjoyglobe on Facebook, Twitter, Instagram and YouTube.

About Amdocs 
Amdocs’ purpose is to enrich lives and progress society, using creativity and technology to build a better connected world. Amdocs and its 26,000 employees partner with the leading players in the communications and media industry, enabling next-generation experiences in 85 countries. Our cloud-native, open and dynamic portfolio of digital solutions, platforms and services brings greater choice, faster time to market and flexibility, to better meet the evolving needs of our customers as they drive growth, transform and take their business to the cloud. Listed on the NASDAQ Global Select Market, Amdocs had revenue of $4.2 billion in fiscal 2020. For more information, visit Amdocs at www.amdocs.com.

Amdocs’ Forward-Looking Statement 
This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs’ growth and business results in future quarters. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general economic conditions, Amdocs’ ability to grow in the business markets that it serves, Amdocs’ ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company’s products and services obsolete, potential loss of a major customer, our ability to develop long-term relationships with our customers, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, the Company specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs’ filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2020 filed on December 14, 2020 and our Form 6-K furnished for the first quarter of fiscal 2021 on February 16, 2021.

Media Contacts:

Deepshikha Kumar
Amdocs Public Relations
E-mail: [email protected]

Yoly C. Crisanto
SVP, Corporate Communications
Globe Telecom, Inc.
Email Address: [email protected] 
Globe Press Room:  https://www.globe.com.ph/about-us/newsroom.html 
Twitter: @talk2GLOBE │ Facebook: http://www.facebook.com/globeph



Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, April 07, 2021 (GLOBE NEWSWIRE) — Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that in connection with hiring Dr. Hideki Garren as Prothena’s Chief Medical Officer, the compensation committee of the Company’s board of directors granted Dr. Garren, an option to purchase 250,000 ordinary shares of the Company. Such stock option has an exercise price per share equal to $24.90, which was the closing trading price on April 5, 2021, the date of the grant. In addition, in connection with hiring a new employee, the compensation committee of the Company’s board of directors granted the individual an option to purchase 30,000 ordinary shares of the Company. Such stock option has an exercise price per share equal to $24.74, which was the closing trading price on April 1, 2021, the date of the grant. The inducement awards will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the respective dates of the grants and 1/48th of the underlying shares vesting monthly thereafter over 36 months. The options were granted pursuant to the Company’s 2020 Employment Inducement Incentive Plan, which was approved by the Company’s board of directors under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

About Prothena

Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a pipeline of novel investigational therapeutics with the potential to change the course of devastating rare peripheral amyloid and neurodegenerative diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.

Contacts:

Media

Ellen Rose, Head of Communications
650-922-2405, [email protected]

Investors

Jennifer Zibuda, Director, Investor Relations & Communications
650-837-8535, [email protected]



EXFO reports second quarter results for fiscal 2021

PR Newswire


  • Sales reached US$69.3 million

  • Bookings attained US$79.3 million, up 8.9% year-over-year

  • IFRS net loss totaled US$2.4 million

  • Adjusted EBITDA amounted to US$3.4 million

QUEBEC CITY, April 7, 2021 /PRNewswire/ – EXFO Inc. (NASDAQ: EXFO) (TSX: EXF), the communications industry’s test, monitoring and analytics experts, reported today financial results for the second quarter ended February 28, 2021.

“EXFO delivered another solid performance in the second quarter of 2021, marked by a robust book-to-bill ratio of 1.15 and healthy cash flows from operations of US$14.7 million,” said EXFO’s CEO Philippe Morin. “I am particularly pleased with our strong bookings that reflect increased market demand, driven by catch-up spending and early deployments of 5G, cloud-based networks, as communications service providers get a better handle on transforming their networks during the coronavirus pandemic. Recent success in securing multi-year contracts bodes well for the footprint expansion of our Nova Adaptive Service Assurance platform with a growing number of RFPs (requests for proposals) for 5G standalone network monitoring systems expected in 2021 and 2022.”

Second Quarter Highlights

  • Sales. The coronavirus outbreak had forced a one-month shutdown of EXFO’s manufacturing facility in Shenzhen, China in February 2020, which negatively impacted second quarter revenues in 2020. With this in mind, sales increased 25.2% year-over-year in the second quarter of 2021 with Test and Measurement (T&M) sales growing 36.8% and Service Assurance, Systems and Services (SASS) sales dropping 2.1%. Sales in the Americas and Europe, Middle East and Africa (EMEA) improved 25.7% and 54.7% year-over-year, respectively, while sales in the Asia-Pacific region fell 18.3%. EXFO’s top customer accounted for 6.8% of sales, while the top three represented 14.3%.
  • Profitability. IFRS net loss totaled US$2.4 million, or –US$0.04 per share, in the second quarter of 2021, while adjusted EBITDA* amounted to US$3.4 million, or 4.9% of sales. The company generated US$14.7 million in cash flows from operations in the second quarter of 2021 and had a net cash position* of US$10.2 million at the end of the quarter.

Selected Financial Information

(In thousands of US dollars)


   Q2 2021


   Q2 2020


    H1 2021


    H1 2020

Test and Measurement sales

$

51,277

$

37,477

$

101,750

$

93,424

Service Assurance, Systems and Services sales

17,565

17,935

38,611

35,684

Foreign exchange gains (losses) on forward exchange contracts

412

(99)

405

(244)

Total sales

$

69,254

$

55,313

$

140,766

$

128,864

Test and Measurement bookings

$

53,665

$

52,003

$

104,913

$

107,012

Service Assurance, Systems and Services bookings

25,272

20,963

43,074

36,012

Foreign exchange gains (losses) on forward exchange contracts

412

(99)

405

(244)

Total bookings

$

79,349

$

72,867

$

148,392

$

142,780

Book-to-bill ratio (bookings/sales)

1.15

1.32

1.05

1.11

Gross margin before depreciation and amortization*

$

38,831

$

31,517

$

80,474

$

74,827

56.1%

57.0%

57.2%

58.1%


Other selected information:

IFRS net earnings (loss)

$

(2,439)

$

(9,021)

$

1,115

$

(9,084)

Amortization of intangible assets

$

1,987

$

1,695

$

4,536

$

3,327

Stock-based compensation costs

$

1,017

$

436

$

1,585

$

923

Restructuring charges

$

    ‒   

$

‒   

$

543

$

‒   

Net income tax effect of the above items

$

(298)

$

(254)

$

(828)

$

(503)

Foreign exchange loss

$

127

$

382

$

373

$

508

Adjusted EBITDA*

$

3,407

$

(4,916)

$

13,356

$

2,628

Quarterly Overview
Sales increased 25.2% to US$69.3 million in the second quarter of fiscal 2021 from US$55.3 million in the coronavirus-impacted second quarter of 2020, which had been marked by a one-month shutdown of the company’s manufacturing facility in Shenzhen, China.

Bookings improved 8.9% to US$79.3 million in the second quarter of fiscal 2021 from US$72.9 million in the same period in 2020. The company’s book-to-bill ratio was 1.15 in the second quarter of 2021.

Gross margin before depreciation and amortization* amounted to 56.1% of sales in the second quarter of fiscal 2021 compared to 57.0% in the second quarter of 2020.

Selling and administrative expenses totaled US$22.9 million, or 33.1% of sales in the second quarter of fiscal 2021 compared to US$24.3 million, or 44.0% of sales, in the second quarter of 2020.

Net R&D expenses attained US$13.5 million, or 19.6% of sales, in the second quarter of fiscal 2021 compared to US$12.6 million, or 22.7% of sales, in the same period last year.

IFRS net loss totaled US$2.4 million, or –US$0.04 per share, in the second quarter of fiscal 2021 compared to US$9.0 million, or –US$0.16 per share, in the second quarter of 2020. IFRS net loss in the second quarter of 2021 included US$2.0 million in amortization of intangible assets, US$1.0 million in stock-based compensation costs, US$0.1 million in foreign exchange loss, and an income tax effect of the above items of $0.3 million. Net loss also included US$0.3 million for an after-tax wage subsidy granted by the Canadian government to help qualifying companies alleviate the effects of the pandemic, as well as US$0.7 million for the excess of the fair value of net identifiable assets acquired over fair value of the total consideration for inOpticals Inc. (now EXFO Taiwan), net of cash acquired for the acquisition.

Adjusted EBITDA* amounted to US$3.4 million, or 4.9% of sales, in the second quarter of fiscal 2021 compared to –US$4.9 million, or -8.9% of sales, in the second quarter of 2020.

Conference Call and Webcast
EXFO will host a conference call today at 5 p.m. (Eastern time) to review second-quarter results for fiscal 2021. To listen to the conference call and participate in the question period via telephone, dial 1-323-289-6576. Please take note the following participant passcode will be required: 8977218. Executive Chairman Germain Lamonde, CEO Philippe Morin and Pierre Plamondon, CPA, Chief Financial Officer and Vice-President of Finance, will participate in the call. An audio replay of the conference call will be available two hours after the event until 8 p.m. on April 14, 2021. The replay number is 1-719-457-0820 and the participant passcode is 8977218. The audio Webcast and replay of the conference call will also be available on EXFO’s website at www.EXFO.com, under the Investors section.

About EXFO
EXFO (NASDAQ: EXFO) (TSX: EXF) develops smarter test, monitoring and analytics solutions for fixed and mobile network operators, webscale companies and equipment manufacturers in the global communications industry. Our customers count on us to deliver superior network performance, service reliability and subscriber insights. They count on our unique blend of equipment, software and services to accelerate digital transformations related to fiber, 4G/LTE and 5G deployments. They count on our expertise with automation, real-time troubleshooting and big data analytics, which are critical to their business performance. We’ve spent over 30 years earning this trust, and today 1,900 EXFO employees in over 25 countries work side by side with our customers in the lab, field, data center and beyond.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and we intend that such forward-looking statements be subject to the safe harbors created thereby. Forward-looking statements are statements other than historical information or statements of current condition. Words such as may, expect, believe, plan, anticipate, intend, could, estimate, continue, or similar expressions or the negative of such expressions are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events and circumstances are considered forward-looking statements. They are not guarantees of future performance and involve risks and uncertainties. Actual results may differ materially from those in forward-looking statements due to various factors including, but not limited to, macroeconomic uncertainty, namely the impact of the coronavirus pandemic on our employees, customers and global operations, including the ability of our suppliers to fulfil raw material requirements and services and our ability to manufacture and deliver our products and services to our customers; the effects of emergency measures related to isolation periods for individuals in affected areas, lockdown restrictions imposed by national governments on businesses in countries where we operate and have employees, and limitations on travel to attract new customers and serve existing ones; deteriorating financial and market conditions as well as a potential recession; trade wars, and our ability to successfully integrate businesses that we acquire; capital spending and network deployment levels in the communications industry (including our ability to quickly adapt cost structures to anticipated levels of business and our ability to manage inventory levels with market demand); future economic, competitive, financial and market conditions; consolidation in the global communications test, monitoring and analytics solutions markets and increased competition among vendors; capacity to adapt our future product offering to future technological changes; limited visibility with regard to the timing and nature of customer orders; delay in revenue recognition due to longer sales cycles for complex systems involving customers’ acceptance; fluctuating exchange rates; concentration of sales; timely release and market acceptance of our new products and other upcoming products; our ability to successfully expand international operations and to conduct business internationally; and the retention of key technical and management personnel. Assumptions relating to the foregoing involve judgments and risks, all of which are difficult or impossible to predict and many of which are beyond our control. Other risk factors that may affect our future performance and operations are detailed in our Annual Report, on Form 20-F, and our other filings with the U.S. Securities and Exchange Commission and the Canadian securities commissions. We believe that the expectations reflected in the forward-looking statements are reasonable based on information currently available to us, but we cannot assure you that the expectations will prove to have been correct. Accordingly, you should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this document. Unless required by law or applicable regulations, we undertake no obligation to revise or update any of them to reflect events or circumstances that occur after the date of this document.

*Non-IFRS Measures
EXFO provides non-IFRS measures (net cash position, gross margin before depreciation and amortization and adjusted EBITDA) as supplemental information regarding its operational performance. Net cash position represents cash and short-term investments, less bank loan and long-term debt. Gross margin before depreciation and amortization represents sales, less cost of sales, excluding depreciation and amortization. Adjusted EBITDA represent net earnings (loss) before interest and other income/expense, income taxes, depreciation and amortization, stock-based compensation costs, restructuring charges, and foreign exchange loss.

These non-IFRS measures eliminate the effect on IFRS results of non-cash statement of earnings elements, restructuring charges as well as elements subject to significant volatility such as foreign exchange gain or loss. EXFO uses these measures for evaluating historical and prospective financial performance, as well as its performance relative to competitors. These non-IFRS measures are also used by financial analysts to evaluate and compare EXFO’s performance against that of competitors and industry players in the company’s sector.

Finally, these measures help EXFO plan and forecast future periods as well as make operational and strategic decisions. EXFO believes that providing this information, in addition to the IFRS measures, allows investors to see the company’s results through the eyes of management, and to better understand historical and future financial performance. More importantly, it enables the comparison of EXFO’s performance on a relatively similar basis against that of other public and private companies in the industry worldwide.

The presentation of this additional information is not prepared in accordance with IFRS. Therefore, the information may not necessarily be comparable to that of other companies and should be considered as a supplement to, not a substitute for, the corresponding measures calculated in accordance with IFRS.

The following table summarizes the reconciliation of adjusted EBITDA to IFRS net earnings (loss), in thousands of US dollars:

Adjusted EBITDA


Q2 2021

Q2 2020


H1 2021

H1 2020

IFRS net earnings (loss) for the period


$


(2,439)

$

(9,021)


$


1,115

$

(9,084)

Add (deduct):

Depreciation and amortization


4,236

3,973


8,959

7,899

Interest and other (income) expense


(137)

285


(2,003)

684

Income taxes


603

(971)


2,784

1,698

Stock-based compensation costs


1,017

436


1,585

923

Restructuring charges


543

Foreign exchange loss


127

382


373

508

Adjusted EBITDA for the period


$


3,407

$

(4,916)


$


13,356

$

2,628

Adjusted EBITDA as a percentage of sales


4.9%

(8.9%)


9.5%

2.0%

 


EXFO Inc.
Condensed Unaudited Interim Consolidated Balance Sheets

(in thousands of US dollars)


As at


February 28,


2021


As at


August 31,


2020


Assets


Current assets

Cash

$

23,868

$

32,818

Short-term investments

458

919

Accounts receivable

Trade

51,521

56,291

Other

5,168

4,055

Income taxes and tax credits recoverable

5,883

4,203

Inventories

41,835

38,865

Prepaid expenses

5,057

5,631

Other assets

3,595

5,493

137,385

148,275


Tax credits recoverable

48,457

48,812


Property, plant and equipment

39,462

39,722


Right-of-use assets

9,082

10,758


Intangible assets

15,025

17,616


Goodwill

41,453

40,290


Deferred income tax assets

4,110

3,633


Other assets

1,656

1,548

$

296,630

$

310,654


Liabilities


Current liabilities

Bank loan

$

10,999

$

32,737

Accounts payable and accrued liabilities

45,856

41,348

Provisions

1,280

3,792

Income taxes payable

384

43

Deferred revenue

26,341

25,785

Other liabilities

4,086

4,032

Current portion of lease liabilities

3,167

3,249

Current portion of long-term debt

1,548

2,076

93,661

113,062


Provisions

2,898

2,782


Deferred revenue

9,155

8,858


Lease liabilities

6,213

7,334


Long-term debt

1,532

2,144


Deferred income tax liabilities

2,795

3,760


Other liabilities

149

151

116,403

138,091


Shareholders’ equity

Share capital

95,164

94,024

Contributed surplus

20,102

19,680

Retained earnings

103,748

102,633

Accumulated other comprehensive loss

(38,787)

(43,774)

180,227

172,563

$

296,630

$

310,654

 


EXFO Inc.
Condensed Unaudited Interim Consolidated Statements of Earnings

(in thousands of US dollars, except share and per share data)


Three months


ended


February 28,


2021


Six months


ended


February 28,


2021


Three months


ended


February 29,


2020


Six months


ended


February 29,


2020


Sales

$

69,254

$

140,766

$

55,313

$

128,864

Cost of sales (1)

30,423

60,292

23,796

54,037

Selling and administrative

22,893

44,499

24,303

48,807

Net research and development

13,548

24,747

12,566

24,315

Depreciation of property, plant and equipment

1,472

2,813

1,424

2,867

Depreciation of right-of-use assets

777

1,610

854

1,705

Amortization of intangible assets

1,987

4,536

1,695

3,327

Interest and other (income) expense

(137)

(2,003)

285

684

Foreign exchange loss

127

373

382

508


Earnings (loss) before income taxes

(1,836)

3,899

(9,992)

(7,386)


Income taxes

603

2,784

(971)

1,698


Net earnings (loss) for the period

$

(2,439)

$

1,115

$

(9,021)

$

(9,084)


Basic and diluted net earnings (loss)
per share

$

(0.04)

$

0.02

$

(0.16)

$

(0.16)


Basic weighted average number of shares
outstanding (000’s)

55,940

55,844

55,603

55,521


Diluted weighted average number of
shares outstanding (000’s)

55,940

57,233

55,603

55,521

(1)

The cost of sales is exclusive of depreciation and amortization, shown separately.

 


EXFO Inc.
Condensed Unaudited Interim Consolidated Statements of Comprehensive Income (Loss)

(in thousands of US dollars)


Three months


ended


February 28,


2021


Six months


ended


February 28,


2021


Three months


ended


February 29,


2020


Six months


ended


February 29,


2020


Net earnings (loss) for the period

$

(2,439)

$

1,115

$

(9,021)

$

(9,084)

Other comprehensive income (loss), net of
income taxes

Items that may be reclassified
subsequently to net earnings (loss)

Foreign currency translation
adjustment

3,921

4,643

(1,319)

(758)

Unrealized gains/losses on forward
exchange contracts

691

947

(718)

(753)

Reclassification of realized gains/losses
on forward exchange contracts

(313)

(469)

173

356

Deferred income tax effect of
gains/losses on forward exchange
contracts

(100)

(134)

146

116

Other comprehensive income (loss)

4,199

4,987

(1,718)

(1,039)


Comprehensive income (loss) for
the period

$

1,760

$

6,102

$

(10,739)

$

(10,123)

 


EXFO Inc.
Condensed Unaudited Interim Consolidated Statements of Changes in Shareholders’ Equity

(in thousands of US dollars)


Six months ended February 29, 2020


Share


capital


Contributed
surplus


Retained
earnings


Accumulated
other
comprehensive
loss


Total


shareholders’
equity

Balance as at September 1, 2019

$

92,706

$

19,196

$

112,173

$

(51,511)

$

172,564

Reclassification of stock-based
compensation costs

1,333

(1,333)

Redemption of share capital

(212)

(13)

(225)

Stock-based compensation costs

930

930

Net loss for the period

(9,084)

(9,084)

Other comprehensive loss

Foreign currency translation
adjustment

(758)

(758)

Changes in unrealized gains/losses
on forward exchange contracts,
net of deferred income taxes
of $116

(281)

(281)

Total comprehensive loss for the period

(10,123)

Balance as at February 29, 2020

$

93,827

$

18,780

$

103,089

$

(52,550)

$

163,146


Six months ended February 28, 2021


Share


capital


Contributed
surplus


Retained
earnings


Accumulated
other
comprehensive
loss


Total


shareholders’
equity

Balance as at September 1, 2020

$

94,024

$

19,680

$

102,633

$

(43,774)

$

172,563

Reclassification of stock-based
compensation costs

1,305

(1,305)

Issuance of share capital

414

414

Share issue expenses

(14)

(14)

Redemption of share capital

(565)

157

(408)

Stock-based compensation costs

1,570

1,570

Net earnings for the period

1,115

1,115

Other comprehensive income

Foreign currency translation
adjustment

4,643

4,643

Changes in unrealized gains/losses
on forward exchange contracts,
net of deferred income taxes
of $134

344

344

Total comprehensive income for the period

6,102

Balance as at February 28, 2021

$

95,164

$

20,102

$

103,748

$

(38,787)

$

180,227

 


EXFO Inc.
Condensed Unaudited Interim Consolidated Statements of Cash Flows

(in thousands of US dollars)


Three months


ended


February 28,


2021


Six months


ended


February 28,


2021


Three months


ended


February 29,


2020


Six months


ended


February 29,


2020


Cash flows from operating activities

Net earnings (loss) for the period

$

(2,439)

$

1,115

$

(9,021)

$

(9,084)

Add (deduct) items not affecting cash

Stock-based compensation costs

1,017

1,585

436

923

Depreciation and amortization

4,236

8,959

3,973

7,899

Gain on disposal of capital assets

(17)

(17)

Write-off of capital assets

10

216

Other income

(669)

(669)

Deferred revenue

1,519

(81)

1,557

(2,815)

Deferred income taxes

(301)

(1,619)

(212)

(654)

Changes in foreign exchange gain/loss

(213)

(1)

902

881

3,133

9,282

(2,365)

(2,634)

Changes in non-cash operating items

Accounts receivable

7,214

6,383

18,539

18,611

Income taxes and tax credits

(997)

223

(3,178)

(2,662)

Inventories

1,924

(681)

(458)

(3,951)

Prepaid expenses

549

1,128

610

988

Other assets

272

1,663

(491)

(456)

Accounts payable, accrued liabilities
and provisions

2,580

(1,253)

(5,580)

(9,273)

Other liabilities

2

(6)

58

42

14,677

16,739

7,135

665


Cash flows from investing activities

Additions to short-term investments

(275)

(505)

(147)

Disposal of short-term investments

948

978

701

1,264

Purchases of capital assets

(1,172)

(2,283)

(2,146)

(4,186)

Cash acquired in a business combination

799

799

300

(1,011)

(1,445)

(3,069)


Cash flows from financing activities

Bank loan

(5,355)

(21,693)

16

8,370

Repayment of lease liabilities

(777)

(1,610)

(846)

(1,690)

Repayment of long-term debt

(578)

(1,159)

(639)

(1,315)

Redemption of share capital

(28)

(408)

(225)

(6,738)

(24,870)

(1,469)

5,140


Effect of foreign exchange rate changes on
cash

237

192

(140)

(128)


Change in cash during the period

8,476

(8,950)

4,081

2,608


Cash – Beginning of the period

15,392

32,818

15,045

16,518


Cash – End of the period

$

23,868

$

23,868

$

19,126

$

19,126

EXFO-F

Cision View original content:http://www.prnewswire.com/news-releases/exfo-reports-second-quarter-results-for-fiscal-2021-301264502.html

SOURCE EXFO Inc.

OpenText to Report Third Quarter Fiscal Year 2021 Financial Results on Thursday, May 6, 2021

PR Newswire

WATERLOO, ON, April 7, 2021 /PRNewswire/ — Open Text Corporation (NASDAQ: OTEX), (TSX: OTEX), announced today that financial results for its third quarter fiscal year 2021 will be released on Thursday, May 6, 2021 at approximately 4:00 p.m. ET.

Teleconference Call

Mark J. Barrenechea, OpenText CEO & CTO, and Madhu Ranganathan, OpenText EVP, CFO will host a conference call on May 6, 2021 at 5:00 p.m. ET to discuss the company’s financial results.


Date:

Thursday, May 6, 2021


Time:

5:00 p.m. ET/2:00 p.m. PT


Length:

60 minutes


Dial-in:

1-800-319-4610 (toll-free)
+1-604-638-5340 (international)

Investors should dial in approximately 10 minutes before the teleconference is scheduled to begin. A replay of the call will be available beginning May 6, 2021 at 7:00 p.m. ET through 11:59 p.m. on May 20, 2021 and can be accessed by dialing 1-855-669-9658 (toll-free) or +1-604-674-8052 (international) and using passcode 6557 followed by the number sign.

For more information or to listen to the call via webcast, please visit: https://investors.opentext.com/events-and-presentations.

About OpenText

OpenText, The Information Company™, enables organizations to gain insight through market leading information management solutions, powered by OpenText Cloud-Editions. For more information about OpenText (NASDAQ: OTEX, TSX: OTEX) visit opentext.com.

Copyright ©2021 Open Text. OpenText is a trademark or registered trademark of Open Text. The list of trademarks is not exhaustive of other trademarks. Registered trademarks, product names, company names, brands and service names mentioned herein are property of Open Text. All rights reserved. For more information, visit: https://www.opentext.com/who-we-are/copyright-information.

OTEX-F

For more information, please contact:

Harry E. Blount

Senior Vice President, Global Head of Investor Relations
Open Text Corporation
415-963-0825
[email protected] 

Cision View original content:http://www.prnewswire.com/news-releases/opentext-to-report-third-quarter-fiscal-year-2021-financial-results-on-thursday-may-6-2021-301264412.html

SOURCE Open Text Corporation

Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire

CAMBRIDGE, Mass., April 7, 2021 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on April 1, 2021, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 27,543 shares of its common stock and an aggregate of 13,792 restricted stock units (RSUs) to 14 new employees under Blueprint Medicines’ 2020 Inducement Plan.

The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Blueprint Medicines, as an inducement material to such individual’s entering into employment with Blueprint Medicines, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

The options have an exercise price of $97.95 per share, which is equal to the closing price of Blueprint Medicines’ common stock on April 1, 2021. Each option will vest as to 25% of the shares underlying such option on the first anniversary of the grant date and as to an additional 1/48th of the shares underlying the option monthly thereafter, in each case, subject to each such employee’s continued employment on each vesting date. Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter, subject to each such employee’s continued employment on each vesting date. The options and RSUs are subject to the terms and conditions of Blueprint Medicines’ 2020 Inducement Plan, and the terms and conditions of the stock option and RSU agreement covering the grant.

About Blueprint Medicines

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301264402.html

SOURCE Blueprint Medicines Corporation

AGNC Investment Corp. Announces Date for First Quarter Earnings Release and Stockholder Call

PR Newswire

BETHESDA, Md., April 7, 2021 /PRNewswire/ — AGNC Investment Corp. (Nasdaq: AGNC) (“AGNC” or the “Company”) announced today it will report first quarter 2021 earnings after market close on April 26, 2021.  AGNC will hold a stockholder call and audio webcast on April 27, 2021 at 8:30 am ET.  Callers who do not plan on asking a question and have internet access are encouraged to utilize the free webcast at www.AGNC.com.  Those who plan on participating in the Q&A or do not have internet available may access the call by dialing (877) 300-5922 (U.S. domestic) or (412) 902-6621 (international).  Please advise the operator you are dialing in for the AGNC Investment Corp. stockholder call.

A slide presentation will accompany the call and will be available at www.AGNC.com.  Select the Q1 2021 Earnings Presentation link to download and print the presentation in advance of the stockholder call.

An archived audio of the stockholder call combined with the slide presentation will be available on the AGNC website after the call on April 27, 2021.  In addition, there will be a phone recording available one hour after the call on April 27, 2021 through May 11, 2021.  Those who are interested in hearing the recording of the presentation can access it by dialing (877) 344-7529 (U.S. domestic) or (412) 317-0088 (international), passcode 10153567.

For further information or questions, please contact Investor Relations at (301) 968-9300 or [email protected]

ABOUT AGNC INVESTMENT CORP.
AGNC Investment Corp. is an internally-managed real estate investment trust that invests primarily in residential mortgage-backed securities for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise or a U.S. Government agency.  For further information, please refer to www.AGNC.com.

CONTACT: Investor Relations – (301) 968-9300

Cision View original content:http://www.prnewswire.com/news-releases/agnc-investment-corp-announces-date-for-first-quarter-earnings-release-and-stockholder-call-301264433.html

SOURCE AGNC Investment Corp.

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire

LEXINGTON, Mass., April 7, 2021 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 1, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 167,300 shares of Curis common stock to five new employees, with a grant date of April 1, 2021 (the “Q2 2021 Inducement Grants”).

Each of the Q2 2021 Inducement Grants has an exercise price per share equal to the closing price of the Company’s common stock on April 1, 2021. Each stock option has a 10 year term and vests over four years, with 25% of the original number of shares underlying the award vesting on the first anniversary of the employee’s date of hire and an additional 6.25% of the original number of shares underlying the award vesting on each successive three-month period thereafter, subject to the employee’s continued service with the Company through the respective vesting dates.  Each stock option was granted as an inducement equity award outside of the Company’s Third Amended and Restated 2010 Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company.

About Curis, Inc.

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma both as a monotherapy and in combination with BTK inhibitor, ibrutinib. Curis is also evaluating CA-4948 in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis’ website at www.curis.com.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/curis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301263965.html

SOURCE Curis, Inc.

John Watters Rejoins FireEye Executive Team as President and Chief Operating Officer

John Watters Rejoins FireEye Executive Team as President and Chief Operating Officer

MILPITAS, Calif.–(BUSINESS WIRE)–
FireEye, Inc. (NASDAQ: FEYE), the intelligence-led security company, announced John Watters has been appointed president and chief operating officer after holding multiple senior leadership and advisory positions at the company, most recently as chairman of the FireEye advisory board. In this role, Watters will bring his operational experience and knowledge of the company to further accelerate our transition to Security as a Service and a Solutions company.

Watters founded iSIGHT Partners and served as its chairman and CEO from November 2006 to February 2016, leading the company to a successful acquisition by FireEye. Following the acquisition, Watters held various senior leadership roles within FireEye, initially as president of the FireEye iSIGHT intelligence business and then as executive vice president of Global Services and Intelligence. He held that position until February 2018, when he was appointed executive vice president and chief strategy officer. Watters stepped down from that role in April 2020 but remained engaged with the company as a senior consultant and then chairman of the company’s Advisory Board.

“He combines the speed and agility of a founder with great operational experience and deep security knowledge,” said FireEye CEO Kevin Mandia. “He’s already familiar with the company and has the knowledge and the passion to accelerate our evolution of our Mandiant solutions business.”

Prior to iSIGHT Partners, Watters was chairman and chief executive officer of iDEFENSE, a security intelligence firm acquired by VeriSign in 2005. In addition, Watters is the founder, a director and president of the STAIRS Program, a non-profit organization supporting inner-city education. He holds a B.S.C degree in Finance from Santa Clara University.

“We have the opportunity to change the game in security, and I’m here to make sure we execute against the challenges ahead,” said Watters. “Kevin and I are aligned on our mission and vision, and I’m excited to join the team to help execute on the strategy.”

About FireEye, Inc.

FireEye is the intelligence-led security company. Working as a seamless, scalable extension of customer security operations, FireEye offers a single platform that blends innovative security technologies, nation-state grade threat intelligence, and world-renowned Mandiant® consulting. With this approach, FireEye eliminates the complexity and burden of cyber security for organizations struggling to prepare for, prevent, and respond to cyber attacks. FireEye has over 9,900 customers across 103 countries, including more than 50 percent of the Forbes Global 2000.

© 2021 FireEye, Inc. All rights reserved. FireEye and Mandiant are registered trademarks or trademarks of FireEye, Inc. in the United States and other countries. All other brands, products, or service names are or may be trademarks or service marks of their respective owners.

Media Inquiries

[email protected]

Investor Inquiries

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Technology Mobile/Wireless Security Other Technology Telecommunications Software Networks Internet Hardware

MEDIA: